JAGUAR HEALTH, INC. Increase (Decrease) in Restricted Cash
JAGUAR HEALTH, INC. (JAGX) reported Increase (Decrease) in Restricted Cash of -$272.13 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-04-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInRestrictedCash · last filed 2018-04-09
- JAGUAR HEALTH, INC. increase (decrease) in restricted cash for the quarter ending 2017-12-31 was -$260.83K.
- JAGUAR HEALTH, INC. increase (decrease) in restricted cash for the quarter ending 2017-09-30 was $500.00K.
- JAGUAR HEALTH, INC. increase (decrease) in restricted cash for the quarter ending 2017-06-30 was -$21.19K.
- JAGUAR HEALTH, INC. increase (decrease) in restricted cash for the quarter ending 2017-03-31 was -$490.10K.
- JAGUAR HEALTH, INC. increase (decrease) in restricted cash for fiscal 2017 was -$272.13K.
- JAGUAR HEALTH, INC. increase (decrease) in restricted cash for fiscal 2016 was -$2.49M, a 182.96% decline from fiscal 2015.
- JAGUAR HEALTH, INC. increase (decrease) in restricted cash for fiscal 2015 was $3.00M.
| Period end | Increase (Decrease) in Restricted Cash 3 month | Increase (Decrease) in Restricted Cash 6 month | Increase (Decrease) in Restricted Cash 9 month | Increase (Decrease) in Restricted Cash 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$260.83K derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-09 | $239.17K derived: sum of 2 quarters · filed 2018-04-09 | $217.98K derived: sum of 3 quarters · filed 2018-04-09 | -$272.13K 10-K · filed 2018-04-09 |
| 2017-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-20 | $478.81K derived: sum of 2 quarters · filed 2017-11-20 | -$11.29K 10-Q · filed 2017-11-20 | -$488.58K derived: sum of 4 quarters · filed 2018-04-09 |
| 2017-06-30 | -$21.19K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2017-08-09 | -$511.29K 10-Q · filed 2017-08-09 | -$988.58K derived: sum of 3 quarters · filed 2018-04-09 | -$1.14M derived: sum of 4 quarters · filed 2018-04-09 |
| 2017-03-31 | -$490.10K 10-Q/A · filed 2017-06-23 | -$967.39K derived: sum of 2 quarters · filed 2018-04-09 | -$1.12M derived: sum of 3 quarters · filed 2018-04-09 | -$2.80M derived: sum of 4 quarters · filed 2018-04-09 |
| 2016-12-31 | -$477.29K derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-09 | -$633.00K derived: sum of 2 quarters · filed 2018-04-09 | -$2.31M derived: sum of 3 quarters · filed 2018-04-09 | -$2.49M 10-K · filed 2018-04-09 |
| 2016-09-30 | -$155.72K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-20 | -$1.83M derived: sum of 2 quarters · filed 2017-11-20 | -$2.01M 10-Q · filed 2017-11-20 | -$3.51M derived: sum of 4 quarters · filed 2017-11-20 |
| 2016-06-30 | -$1.68M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2017-08-09 | -$1.86M 10-Q · filed 2017-08-09 | -$3.36M derived: sum of 3 quarters · filed 2017-08-09 | |
| 2016-03-31 | -$178.74K 10-Q/A · filed 2017-06-23 | -$1.68M derived: sum of 2 quarters · filed 2017-06-23 | ||
| 2015-12-31 | -$1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-15 | $3.00M 10-K · filed 2017-02-15 | ||
| 2015-09-30 | $4.50M 10-Q · filed 2016-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |